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reatment efﬁcacy of 3-day or 7-day administration of
aropenem sodium for acute uncomplicated cystitis
. Hamasuna1,∗, K. Tanaka2, H. Hayami3, M. Yasuda4, S.
akahashi5, K. Kobayashi6, M. Matsumoto1, K. Sho1, H. Kiyota7,
. Yamamoto8, S. Arakawa2, T. Matsumoto1
University of Occupational and Environmental Health, Japan,
itakyushu, Japan
Kobe University Graduate School of Medicine, Kobe, Japan
Kagoshima University Hospital, Kagoshima, Japan
School of Medicine, Gifu University, Gifu, Japan
Sapporo Medical University, Sapporo, Japan
Hiroshima Graduate School of Biomedical Sciences, Hiroshima Uni-
ersity, Hiroshima, Japan
Katsushika Medical Center, Jikei University, Tokyo, Japan
Hyogo College of Medicine, Nishinomiya, Japan
Background: Faropenem (FRPM), the only penemused in Japan,
s known to have low inducibility to be resistant to antimicrobials.
n the present study, we investigated efﬁcacy of FRPM to acute
ncomplicated cystitis (AUC) and the optimal periods of admin-
stration with FRPM.
Methods: A randomized, open label, comparative multicen-
er study was conducted on female outpatients diagnosed with
UC at 35 participating institutions across Japan. The criteria to
ntry patients and the evaluation of efﬁcacy conformed to the
apanese Guidelines for Clinical Research of Antimicrobial Agents
n Urogenital Infections: the First Edition. FRPM with 200 mg,
.o. three times per day was administered to patients allocated to
ither the 3-day or 7-day administration group (target sample, 100
er group) using the central registration method; a registration
orm of entried patients were faxed and allocated by the clinical
rials ofﬁce (CREC Net, Kitakyushu, Japan). Bacteriological investi-
ation was conducted at Kyurin Corporation (Kitakyushu, Japan).
acteriological and clinical efﬁcacies were evaluated 5 to 9 days
ost-administration of FRPM.
Results: A total of 200 patients were registered between May
010 and May 2011 (3-day administration: n=97; median age, 49
ears old; age-range, 20-80 years. 7-day administration: n=103;
edian age, 47 years old; age-range, 21-81 years). Exclusion crite-
ia comprised insufﬁcient bacterial count at entry, lost to follow-up
nd withdrawal from the study. Microbiological outcome revealed
hat 7-day administration (n=64) was signiﬁcantly more effective
han 3-day administration (n=62) (eradication: 84.4% vs. 62.9%;
ersistence: 7.8% vs. 24.2%; replace: 7.8% vs. 12.9%; p=0.018). The
linical outcome tended to be greater in 7-day administration than
n 3-day administration, but differenceswere not signiﬁcant (82.6%
57/69] vs. 93.0% [(66/71]; p=0.061).Conclusion: Seven-day administration of FRPM (200mg, p.o.
hree timesperday)providesoptimal administration route forAUC.
ttp://dx.doi.org/10.1016/j.ijid.2012.05.622fectious Diseases 16S (2012) e317–e473
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Carbapenem therapy for bacteremia due to extended-spectrum
-lactamase-producing Escherichia coli or Klebsiella pneumo-
niae: Implications of Ertapenem susceptibility
P.-R. Hsueh1,∗, W.-C. Ko2
1 National Taiwan University Hospital, Taipei, Taiwan, R.O.C
2 National Cheng Kung University Medical College and Hospital,
Tainan, Taiwan, R.O.C
Background: Arbapenem susceptibility breakpoints for Enter-
obacteriaceae issued by the Clinical and Laboratory Standards
Institute (CLSI) had been recently revised and different from those
by the European Committee on Antimicrobial Susceptibility Test-
ing. Clinical impact of such a revision remains to be deﬁned.
Methods: A retrospective study evaluated patients treated with
a carbapenem for bacteremia caused by extended-spectrum beta-
lactamase (ESBL)-producing organisms at two medical centers in
Taiwan. Clinical characteristics, outcome, and risk factors of mor-
tality of these patients were analyzed.
Results: Of 251 patients with bacteremia treated by a car-
bapenem were identiﬁed. Among ESBL-producing E. coli and K.
pneumoniae, susceptibility rates of ertapenem were 83.8% and
76.4%, respectively, meropenem 100% and 99.3%, and imipenem
100% and 97.9%. The patients receiving inappropriate therapy
had a higher sepsis-related mortality than those with appropri-
ate therapy (P=0.002), irrespective of ertapenem, imipenem or
meropenem therapy. However, if the breakpoint of ertapenem sus-
ceptibility is 0.5 g/ml, the mortality of bacteremic episodes due
to isolates with MICs ≤0.5 g/ml is similar to those with MICs
>0.5 g/ml (P=0.8). Multivariate analysis of variables related to
sepsis-related mortality revealed that the presence of severe sep-
sis (odds ratio [OR], 9.70; 95% conﬁdence interval [CI], 3.15-29.86;
P <0.001), hospital-onset bacteremia (OR, 5.61; 95% CI, 1.64-19.13;
P=0.006), and ertapenem-nonsusceptible isolates (OR, 5.17; 95%
CI, 2.03-13.13; P=0.001) were independent risk factors.
Conclusion: Infections due to the causative isolates with
ertapenem MIC values ≤0.25 g/ml were associated with a favor-
able outcome if treated by a carbapenem. Such a ﬁnding supports
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Randomized clinical trial of mebendazole, metronidazol and
praziquantle in the treatment of giardiasis in Islamic Republic
of Iran 2008
R. Imani ∗, A. Khoshdellshahrekord medical university, Shahrekord, Iran, Islamic Republic of
Background: Giardia lamblia (G.L) is a common intestinal par-
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istributed all over the world, and the infection is prevalent in
oth developing and developed countries. Although 5- nitroim-
dazole compounds have been used for Giardiasis treatment for
everal years, the increasing number of reports of refractory cases
nd side effects of some drugs resulted in establishment of more
nvestigation for new compounds.The aim of present study was to
ompare the efﬁcacy of praziquantel and Mebendazole, given as a
ingle – dose, with Metronidazole, given 5-7 days, in the treatment
f Giardiasis.
Methods: In a randomized clinical trial, 90 subjects, eachproven
o be infected with G.L by the microscopically examination of fecal
ample, were randomly allocated to 3 groups, Group 1 was given
raziquantel as a single – dose, Groups 2 mebendazole as a single –
oseandGroup3metronidazole for7days, parasitological curewas
ocumented when there was 3 times negative stool examination
or G.L at 7 – 10 days after therapy
Results: Seventeen of 30 individuals (56.6%) treated with praz-
quantel and 15 of 30 individuals (50%) treated with mebendazole
nd 28 of 30 individuals (93%) treated with metronidazole were
ured. Cure rate between praziquantel and mebendazole wasn’t
igniﬁcantly different) P>0.05), but between these (praziqunted,
ebendazole) and metronidazole, the difference was signiﬁcant
P <0.05). No side effects of these drugs were observed.
Conclusion: Metronidazole as a standard dose is more effective
n the treatment of Giardiasis.
ttp://dx.doi.org/10.1016/j.ijid.2012.05.624
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angosteen spray for efﬁcacious treatment of streptococcal
haryngitis
. Supajatura1,∗, Y. Pongpaibul2, P. Tharavichitkul3
Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand
Faculty of Pharmacy, Payab University, Chiang Mai, Thailand
Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand
Background: Crude ethanolic extract of mangosteen rind had
otent inhibitory activity against Streptococcus pyogenes with inhi-
ition titer of 51,200 – 102,400 (Pongpaibul, The 3rd World
ongress on Medicinal and Aromatic Plants for Human Welfare
003).When it was prepared as throat spray(MTS), it showed good
ntibacterial activity with stable activity for pharyngitis. To coﬁrm
ts efﬁcacy for treatment of streptococcal pharyngitis by comparing
ith amoxicillin or placebo.
Methods: In the ﬁrst clinical study (Febuary to December 2008),
total of 201 suspected streptococcal pharyngitis patientswithdis-
inct exudative pharyngitis(score 4) were included in this study.
hroat swab culture and random treatment with amoxicillin or
TS were requested for them. For the second study(June 2552 to
ctober 2553), a total of 253 cases with randomly treated with
angosteen throat spray or placebo by double blind experiment
ere included. The treatment results were followed up on the 3rd
r 10th dayResults: In the ﬁrst study, 67 of 201 (33.3%) were found as
HS infected patients (including 27 MTS group and 40 Amoxycillin
roup) and the treatment results of the MST group and Amoxy-
illin group were improved with 77.8% (21 of 27) and 82.5% (33 offectious Diseases 16S (2012) e317–e473 e441
40), respectively after following up on the 3rd day. For the second
study, 103 (40.7%) of BHS infected patients(including 57MTS group
and 46 placebo group) were detected and the treatment results of
76 patients(including 43MTS group and 33 Placebo group)with the
2nd followup-throat swab cultures could be followedupon the 3rd
day. However 6 BHS isolates (13.9%) were found in the MTS group
but 29 BHS isolates (87.9%) were recovered in the Placebo group.
The3rd day-follow up-treatment results of 103 BHS positive cases
indicated that the MTS group and Placebo group were improved
with 89.5% (51 of 57) and 15.2% (7 of 46), respectively. And all of
the MTS treatment patients were cured completely after following
up to 10 days.
Conclusion: The mangosteen throat spray can be used to treat
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Rationalizing the use use of Linezolid through Antibiotic Stew-
ardship program in a tertiary care teaching hospital in Pakistan
S. Ahsan ∗, F. Mahmood, F. Ali
Aga Khan University Hospital, Karachi, Pakistan
Background: Rationalizing the use of antibiotics which are
considered last resort against organisms resistant to ﬁrst line
agents has remained the top priority of antibiotic stewardship
programs in healthcare institutions. The problem is particularly
important in developing countries where more discrepancies have
been reported and the range of available antimicrobials for resis-
tant organisms is also quite narrow. We conducted this study in
our hospital which is a 550 bed tertiary care, ISO certiﬁed, JCIA
accredited teaching hospital in Pakistan.
Methods: Rational use of antibiotics is the dashboard indicator
of the hospital in which the Pharmacy Department conducts retro-
spective drug utilization reviews (DUR) of the selected antibiotics.
When Linezolid was added in the formulary, hospital’s Antibiotic
Subcommittee (ABSC) approved its utilization criteria. It was listed
as restricted antibiotic as being the only drug available for treating
Vancomycin Resistant Enterococcus (VRE).
Staff was made aware regarding the criteria through hospital’s
published Antibiotic Guideline, ﬂyers, computer alerts, educational
sessions and through clinical pharmacists assigned in wards.
First DUR was conducted 3 months after the formulary addi-
tion. The compliance was found to be only around 80%; therefore
ABSC further posed mandatory ID/Micro consults irrespective of
the C/S reports of a patient prior to initiation of therapy. More-
over empiric use of Linezolid was also restricted. Pharmacy would
dispense Linezolid only when a verbal endorsement is given by
ID/Micro directly to pharmacy. Further 3 months later, second clin-
ical audit was perforemd and the compliance to criteria increased
to 94%.
Results: Second DUR revealed good compliance i.e. 94% to Line-
zolid utilization criteria. Areas of improvement were noted along
with degree of compliancewas also determined in different clinical
departments.
